Summary
The AI claims provided cannot be verified against the supplied FDA label excerpts because the prompt does not include the actual label text sufficient to support/contradict each specific claim (e.g., immunosuppression/immune effects, mechanism, 'immune-related concern,' TTP/HUS mechanism context, specific allergy reaction types, and blood count effects). As a result, alignment cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
Acyclovir is an antiviral medicine that treats certain viral infections.
The provided label excerpts specify indications (herpes zoster, genital herpes, chickenpox) but do not explicitly support the generalized phrasing 'antiviral medicine that treats certain viral infections' as a claim statement (mechanism/antiviral categorization not explicitly in provided excerpts).
Acyclovir is not generally considered an immune-suppressing drug like corticosteroids or chemotherapy.
No label excerpt provided supports or mentions acyclovir as immune-suppressing vs not; this is not directly supported by the supplied label text.
Acyclovir blocks viral DNA replication rather than weakening immune cells.
No label excerpt provided in the prompt states the mechanism as 'blocks viral DNA replication' or contrasts it with immune-cell weakening.
Any illness severe enough to require antivirals can temporarily affect immune function.
Not supported by the provided label excerpts.
Acyclovir can cause allergic-type reactions (immune-mediated hypersensitivity) such as rash, hives, or swelling.
The label excerpt lists 'Anaphylaxis, angioedema' but does not provide rash/hives/swelling as 'such as' examples; immune-mediated hypersensitivity framing and specific examples are not supported by the provided excerpts.
Rarely, acyclovir can affect blood counts in some people.
The provided adverse reaction excerpts do not mention blood count effects.
A history of medication allergy to acyclovir/valacyclovir is an immune-related concern.
Label excerpt supports contraindication for hypersensitivity to acyclovir or valacyclovir, but the phrase 'immune-related concern' is not present in the provided text; only the hypersensitivity contraindication is supported.
Acyclovir is processed by the kidneys.
The provided label excerpt states clearance is dependent on renal function and that dose adjustment is recommended in renal impairment, but it does not explicitly state 'processed by the kidneys' in that form.
Poor kidney function can raise acyclovir drug levels and increase the risk of serious side effects.
The label excerpts provided establish that half-life/clearance depend on renal function and dosage adjustment is recommended in renal impairment, and renal failure has been observed; however, the specific causal phrasing 'raise drug levels' and 'increase risk of serious side effects' is not directly supported verbatim by the provided excerpts.
A severely weakened immune system (e.g., after transplant or during cancer treatment) may require close monitoring and dosing adjustment of acyclovir by clinicians.
The provided warnings mention TTP/HUS occurring in immunocompromised patients receiving acyclovir, but the label excerpts provided do not mention post-transplant or cancer treatment requiring dosing adjustment, nor do they provide 'close monitoring' language specific to immune status.
Acyclovir can be used in people who also take other medicines, including immunosuppressants.
No supplied label excerpt supports this statement. The provided drug interaction excerpt is limited (e.g., probenecid with intravenous acyclovir) and does not address immunosuppressants.
The key issue when using acyclovir with immunosuppressants is usually drug dosing and kidney safety, not that acyclovir turns down the immune system.
The provided label excerpts do not address immunosuppressants coadministration or 'acyclovir turns down the immune system' framing.
Because acyclovir is not an immunosuppressant, it generally does not increase infection risk in the way immune-suppressing drugs do.
No provided label excerpt supports claims about infection risk comparisons or whether acyclovir is an immunosuppressant.
Contradictions
Low
AI Statement
Acyclovir is not generally considered an immune-suppressing drug like corticosteroids or chemotherapy.
Label Reference
Section 5 (Warnings): 'Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS)… has occurred in immunocompromised patients receiving acyclovir therapy.'
Important Omissions
FDA-labeled indications and dosing regimens for the specific infection being discussed (herpes zoster, genital herpes initial/recurrent, chickenpox; dosing details by population).
Importance:
Moderate
Renal impairment dose modification and hemodialysis additional-dose instruction (Table 3 dosing and post-dialysis dose).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most statements are mechanistic/general or compare to other drug classes and are not directly supported by the supplied label excerpts; however, the provided label excerpts do support renal failure as a warning and hypersensitivity contraindication. The lack of direct label support for multiple immune-related claims prevents confident on-label alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple immune-related and mechanism claims are not supported by the supplied prescribing information excerpts; several safety statements (e.g., blood count effects) are not supported by provided label text.
Suggested Improvement
Restrict claims to information explicitly present in the provided label excerpts (indications in Section 1; dosing and renal/hemodyalisis adjustments in Section 2; hypersensitivity contraindication in Section 4; renal failure and TTP/HUS in immunocompromised patients in Section 5; adverse reactions explicitly listed in Section 6; renal-dependent clearance in Section 12). Avoid comparative statements about immunosuppression, infection risk, viral DNA replication mechanism, and blood count effects unless supported by the provided label text.